Appendix B. Sources of evidence considered by the Committee
A. The Evidence Review Group (ERG) report for this appraisal was prepared by Liverpool Reviews and Implementation Group (LRiG):
-
Bagust A et al Pemetrexed for the treatment of relapsed non-small cell lung cancer, September 2006.
B. The following organisations accepted the invitation to participate in this appraisal. They were invited to comment on the draft scope. Organisations listed in I were also invited to make written submissions. Organisations listed in II gave their expert views on pemetrexed by providing a written statement to the Committee. Organisations listed in I and II have the opportunity to appeal against the final appraisal determination.
I) Manufacturer/sponsor
-
Eli Lilly and Company Ltd.
II) Professional/specialist and patient/carer groups:
-
British Thoracic Oncology Group
-
British Thoracic Society
-
Cancer Networks Pharmacists Forum
-
Cancer Research UK
-
CancerBackup
-
Department of Health
-
Roy Castle Lung Cancer Foundation
-
Royal College of Nursing
-
Royal College of Pathologists
-
Royal College of Physicians, Medical Oncology Joint Special Committee
-
Tenovus Cancer Information Centre
-
Welsh Assembly Government
III) Commentator organisations (did not provide written evidence and without the right of appeal):
-
British National Formulary
-
British Thoracic Oncology Group
-
MRC CTU - Lung Cancer and Mesothelioma Group
-
National Collaborating Centre for Cancer
-
NHS Quality Improvement Scotland
-
Roche Products Ltd.
-
Sanofi-Aventis
C. The following individuals were selected from clinical specialist and patient advocate nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on pemetrexed by providing oral evidence to the Committee.
-
Dr Jesme Baird, Director of Patient Care, nominated by the Roy Castle Lung Cancer Foundation – patient expert
-
Professor David R Ferry, Medical Oncologist, New Cross Hospital, Wolverhampton, nominated by the Royal College of Physicians – clinical specialist
-
Dr Mary O'Brien, Consultant Medical Oncologist, Institute of Cancer Research, nominated by the Institute of Cancer Research – clinical specialist
-
Dr Elizabeth Sawicka, Consultant, Princess Royal University Hospital, nominated by The British Thoracic Society – clinical specialist